Search Results - "Tedeschi, Alessandra"

Operational Improvements to Reduce the Climate Impact of Aviation—A Comparative Study from EU Project ClimOP.

Authors: Zengerling, Zarah Lea Dal Gesso, Sara Linke, Florian et al.

Source: Applied Sciences (2076-3417); Aug2023, Vol. 13 Issue 16, p9083, 31p

Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to Ignore.

Authors: Camerini, Andrea Inno, Alessandro Canale, Maria Laura et al.

Source: International Journal of Molecular Sciences. Sep2025, Vol. 26 Issue 18, p9100. 17p.

Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.

Authors: Tedeschi, Alessandra Picardi, Paola Ferrero, Simone et al.

Source: Leukemia & Lymphoma. Sep2015, Vol. 56 Issue 9, p2637-2642. 6p.

Mapping the literature on the factors that influence cybersecurity. A bibliographic coupling analysis.

Authors: Larena-Luengo, Alberto Martínez Herraiz, Jose Javier Ferrer-Oliva, Mikel et al.

Source: Cogent Business & Management. Dec2025, Vol. 12 Issue 1, p1-34. 34p.

Is HBV prophylaxis required during CLL treatment with ibrutinib?

Authors: Tedeschi, Alessandra Frustaci, Anna Maria Mazzucchelli, Maddalena et al.

Source: Leukemia & Lymphoma. Dec2017, Vol. 58 Issue 12, p2966-2968. 3p.

Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors: Woyach, Jennifer Tedeschi, Alessandra Munir, Talha et al.

Source: Leukemia & Lymphoma. Dec 2021, Vol. 62 Issue 13, p3278-3282. 5p.

Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia.

Authors: Deodato, Marina Frustaci, Anna Maria Zappaterra, Arianna et al.

Source: Leukemia & Lymphoma. Dec2024, Vol. 65 Issue 14, p2096-2107. 12p.

Leveraging human factors in cybersecurity: an integrated methodological approach.

Authors: Pollini, Alessandro Callari, Tiziana C. Tedeschi, Alessandra et al.

Source: Cognition, Technology & Work; May2022, Vol. 24 Issue 2, p371-390, 20p

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.

Authors: Burger, Jan A. Robak, Tadeusz Demirkan, Fatih et al.

Source: Leukemia & Lymphoma. Jun2022, Vol. 63 Issue 6, p1375-1386. 12p.

Security economics: an adversarial risk analysis approach to airport protection.

Authors: Cano, Javier Ríos Insua, David Tedeschi, Alessandra et al.

Source: Annals of Operations Research; Oct2016, Vol. 245 Issue 1/2, p359-378, 20p

From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.

Authors: Visentin, Andrea Pravato, Stefano Castellani, Francesca et al.

Source: Cancers. Mar2022, Vol. 14 Issue 6, p1562. 16p.

Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia.

Authors: Ricci, Francesca Tedeschi, Alessandra Montillo, Marco et al.

Source: Mediterranean Journal of Hematology & Infectious Diseases. 2011, Vol. 3 Issue 1, p1-10. 10p.

Current Therapeutic Options for Chronic Lymphocytic Leukemia.

Authors: Tedeschi, Alessandra Vismara, Eleonora Ricci, Francesca et al.

Source: Current Medical Literature: Leukemia & Lymphoma. 2009, Vol. 17 Issue 4, p93-104. 12p. 3 Charts.

Author Index.

Source: British journal of haematology Apr2024 Supplement 1; Vol. 204.

Journal Info: Publisher: Wiley-Blackwell ISSN: 0007-1048

Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia.

Authors: Tedeschi, Alessandra Benevolo, Giulia Varettoni, Marzia et al.

Source: Cancer (0008543X). Jan2012, Vol. 118 Issue 2, p434-443. 10p.

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.

Authors: Frustaci, Anna Maria Deodato, Marina Zamprogna, Giulia et al.

Source: Cancers. Mar2023, Vol. 15 Issue 5, p1504. 16p.

The management of chronic lymphoproliferative disorders at the time of SARS-Covid2 pandemic: weathering the storm.

Authors: Frustaci, Anna Maria Zamprogna, Giulia Deodato, Marina et al.

Source: Leukemia & Lymphoma. Dec2020, Vol. 61 Issue 13, p3278-3279. 2p.

BSH 2023 author index.

Source: British journal of haematology Apr2023 Supplement 1; Vol. 201.

Journal Info: Publisher: Wiley-Blackwell ISSN: 0007-1048

Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?

Authors: Deodato, Marina Frustaci, Anna Maria Zamprogna, Giulia et al.

Source: Hemato. Dec2022, Vol. 3 Issue 4, p689-703. 15p.

A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.

Authors: Luminari, Stefano Goldaniga, Maria Cesaretti, Marina et al.

Source: Leukemia & Lymphoma. Apr2016, Vol. 57 Issue 4, p880-887. 8p.